Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) OS at 36 months was 81.9% (95% CI, 66.8 ...

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial Clinical trials frequently ...

(Vienna, August 8, 2022, 10:30 a.m. CEST)--An interim analysis of overall survival data from the IMpower010 trial showed an overall survival trend in favor of atezolizumab in the PD-L1 TC > 1% stage ...

Alecensa (alectinib) demonstrated a 22% reduction in the risk of death compared with Xalkori (crizotinib) in the frontline setting of patients with advanced ALK-positive non–small cell lung cancer ...

The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its ...

Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin’s lymphoma showed long-term progression-free survival benefits with first-line therapy with ...

An analysis of secondary endpoints showed that GLP-1 agonist users had a significantly lower risk of myocardial or cerebral ...

NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival ...

Coronavirus disease 2019 (COVID-19) has spread to nearly every country in the world and caused over 5.69 million deaths. The initial emergence and rapid spread of severe acute respiratory syndrome ...

Industry watchers who cheered on Summit Therapeutics’ claim that the first global phase 3 trial of its Akeso-partnered PD-1xVEGF drug showed consistent benefit between China and Western populations ...